figs3.

Figure S3. Antiviral activity of PLE and remdesivir as observed in the combination assay. Vero E6 cells were infected with SARS-CoV-2 in the presence of serial dilutions of PLE combined with remdesivir. Cells were subsequently harvested at 72 h p.i. and cell viability was quantified with the MTT assay. The absorbance of drug-treated cells was normalized to mock-infected cells (arbitrarily set to 1). The ratio of drug inhibition elicited by the combination of PLE and remdesivir was calculated with the HSA reference synergy model available in the SynergyFinder software (version 2). The dose-response plot (A) as well as the two-dimensional (B) and three-dimensional (C) synergy maps are reported. Results should be considered representative of those obtained from two independent experiments carried out in duplicate.